A World First at the Montreal Heart Institute - Discovery of a personalized therapy for cardiovascular disease

Food and Healthcare Press Releases Tuesday January 13, 2015 16:45
MONTREAL--13 Jan--PRNewswire/InfoQuest
-- Important reduction in events including heart attacks and deaths in patients with the appropriate genetic background to respond to a new medication

Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths. These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.

The team led by Drs Jean-Claude Tardif and Marie-Pierre Dube performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.

"These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world" said lead investigator Jean-Claude Tardif MD, director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.

The investigators tested multiple genetic markers across the entire genome in a procedure called genome-wide association study. "We used state-of-the-art genetic and statistical techniques to demonstrate that the effect of the patient's genetic profile was only observed in those treated with dalcetrapib and not placebo. We want to provide patients with additional personalized cardiovascular therapies in the years to come, for more efficacious and safer medicines", commented Marie-Pierre Dube PhD, director of the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.

Dr. Jean-Claude Tardif is available for interviews.
To read the article: http://bit.ly/1tZSSG9
To consult the Journal of the American heart Association website : http://circgenetics.ahajournals.org
Media Invitation :
Wednesday January 14 2015 at 10:30 AM
Auditorium Jean Parisien at the Montreal Heart Institute
5000, Belanger street, Montreal, Quebec H1T 1C8
RSVP : Lise Plante +1-514-376-3330 ext 3898
Dr Jean-Claude Tardif will present the study highlights.
Dr Jean-Claude Tardif
https://www.icm-mhi.org/en/research/researchers/493-jean-claude-tardif
Dre Marie-Pierre Dube
https://www.icm-mhi.org/fr/recherche/chercheurs/501-marie-pierre-dube
About the Montreal Heart Institute: www.icm-mhi.org
About the Montreal Heart Institute Foundation: www.icm-mhi.org
Lise Plante MBA, Communications and Marketing Director, Montreal Heart Institute Foundation, Phone: +1-514-376-3330, ext. 3898, lise.plante@icm-mhi.org , facebook.com/institutcardiologiemontreal, @ICMtl

Latest Press Release

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

United Nations Political Declaration on Universal Health Coverage Finally has Some Teeth

FDI World Dental Federation (FDI) welcomes the long overdue commitment to strengthening oral health in the UN Political Declaration on Universal Health Coverage (UHC). The declaration will be officially adopted by world leaders at the UN High-Level...

Ozempic(R) Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza(R) and Canagliflozin in People With Type 2 Diabetes

Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagliflozin...

Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels

Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in...

Upjohn Thailands commitment to non-communicable diseases

Upjohn Thailand announced its commitment and integrated strategy to improve patient health and relieve the burden of non-communicable diseases (NCDs) with trusted, quality medicines for every patient, everywhere. As Upjohn expands its capability in...

Related Topics